What is the recommended plan of care for a patient with pulmonary embolism, status post intravenous heparin infusion in the hospital, now managed on apixaban (Eliquis) in the primary care setting?

Plan of Care for Pulmonary Embolism Post-Heparin Drip, Now on Apixaban in Primary Care

Continue apixaban at 5 mg twice daily after completing the initial 7-day course of 10 mg twice daily, and maintain therapeutic anticoagulation for a minimum of 3 months, with duration ultimately determined by whether the PE was provoked or unprovoked. 1

Anticoagulation Management

Your patient has appropriately transitioned from intravenous heparin to apixaban, which aligns with the 2019 ESC Guidelines that recommend NOACs (including apixaban) as the preferred oral anticoagulant for PE patients 1. The dosing regimen should be:

• Days 1-7: Apixaban 10 mg orally twice daily (likely completed in hospital)
• After day 7: Apixaban 5 mg orally twice daily 2

Contraindications to Monitor

Ensure the patient does NOT have:

• Severe renal impairment (creatinine clearance <30 mL/min)
• Antiphospholipid antibody syndrome (requires VKA instead)
• Moderate to severe liver disease 1, 3

Duration of Anticoagulation - Critical Decision Point

This is the most important clinical decision you will make in primary care. The 2019 ESC Guidelines provide clear stratification 1:

Discontinue at 3 Months If:

• First PE with a major transient/reversible risk factor (e.g., recent surgery, prolonged immobilization, trauma, estrogen therapy)
• Patient has completed 3 months of therapeutic anticoagulation

Continue Indefinitely If:

• Unprovoked PE (no identifiable reversible risk factor)
• Recurrent VTE (any prior PE or DVT episode not related to major transient risk factor)
• Patient tolerates anticoagulation without bleeding complications

Special Consideration - Extended Prophylaxis:

After completing at least 6 months of full-dose anticoagulation for unprovoked PE, consider reducing to apixaban 2.5 mg twice daily for extended prophylaxis 2. This lower dose reduces recurrence risk while minimizing bleeding risk.

Mandatory Follow-Up Schedule

3-6 Month Routine Re-evaluation 1:

• Assess for persistent dyspnea, exercise intolerance, or functional limitation
• Screen for chronic thromboembolic pulmonary hypertension (CTEPH)
• Perform echocardiography if symptomatic
• Consider ventilation/perfusion (V/Q) scan if mismatched perfusion defects suspected beyond 3 months

Regular Interval Assessments (every 3-6 months for extended anticoagulation) 1:

• Drug adherence and tolerance
• Bleeding events (any epistaxis, hematuria, melena, excessive bruising)
• Renal function (creatinine clearance)
• Hepatic function (transaminases)
• Bleeding risk reassessment using validated scores

Monitoring for Complications

Bleeding Risk Assessment

Immediately discontinue apixaban and seek emergency care if 2:

• Active pathological hemorrhage
• Signs of intracranial bleeding (severe headache, altered mental status, focal deficits)
• Hemodynamic instability from bleeding

Common bleeding manifestations to counsel patients about:

• Epistaxis lasting >10 minutes
• Hematuria (pink/red urine)
• Melena or hematochezia
• Excessive bruising
• Prolonged bleeding from minor cuts

Recurrent VTE Surveillance

Monitor for symptoms suggesting recurrent PE or DVT:

• New or worsening dyspnea, chest pain, hemoptysis
• Unilateral leg swelling, pain, warmth, erythema

If hemodynamic deterioration occurs on anticoagulation, this represents treatment failure requiring rescue thrombolytic therapy 1.

Drug Interactions - Critical Pitfall

Reduce apixaban dose by 50% (to 2.5 mg twice daily) if patient requires 2:

• Combined P-glycoprotein AND strong CYP3A4 inhibitors:
  • Ketoconazole, itraconazole, ritonavir, clarithromycin

Avoid coadministration if already on 2.5 mg twice daily 2.

Increased bleeding risk with concomitant use of 2:

• Aspirin or antiplatelet agents
• NSAIDs
• SSRIs/SNRIs
• Other anticoagulants

Perioperative Management

For elective procedures 2:

• High bleeding risk procedures: Stop apixaban 48 hours before
• Low bleeding risk procedures: Stop apixaban 24 hours before
• No bridging anticoagulation required during the 24-48 hour interruption
• Resume apixaban when adequate hemostasis established post-procedure

Neuraxial Anesthesia - Absolute Contraindication Window

If spinal/epidural anesthesia or lumbar puncture planned 2:

• Do NOT remove indwelling catheter until 24 hours after last apixaban dose
• Do NOT give next apixaban dose until 5 hours after catheter removal
• If traumatic puncture occurs, delay apixaban for 48 hours
• Risk of epidural/spinal hematoma with permanent paralysis

Patient Education Essentials

Medication adherence:

• Take twice daily, approximately 12 hours apart
• If dose missed, take as soon as remembered on same day; do NOT double dose 2
• Can be taken with or without food

Warning signs requiring immediate medical attention:

• Any unusual bleeding that won't stop
• Blood in urine or stool
• Severe headache or dizziness
• Weakness, numbness, or vision changes

Common Pitfalls to Avoid

1. Do NOT use sPESI score alone for risk stratification in primary care—it has limitations for selecting appropriate candidates for outpatient management 4

2. Do NOT routinely check PT/INR or anti-Xa levels—these are not useful for monitoring apixaban and do not guide dosing 2

3. Do NOT assume all PE patients need indefinite anticoagulation—provoked PE with reversible risk factors should stop at 3 months 1

4. Do NOT forget the 3-6 month follow-up—this is when CTEPH screening should occur, as symptoms may be subtle 1

The evidence strongly supports apixaban as safe and effective for PE treatment 3, 5, 6, with lower bleeding rates compared to warfarin and equivalent efficacy in preventing recurrent VTE 7.